BLFS
HealthcareBioLife Solutions, Inc.
$25.31
+$1.42 (+5.94%)
Jan 5, 2026
Price History (1Y)
Analysis
BioLife Solutions, Inc. is a healthcare company operating in the medical instruments and supplies industry. With a market capitalization of $1.22 billion, it ranks among larger players in its sector, having generated revenue of $100.14 million in the trailing twelve months (TTM). The company has a workforce of 159 employees. The financial health of BioLife Solutions is characterized by negative profitability metrics. Its gross margin stands at 64.3%, while operating and profit margins are -0.3% and -3.2%, respectively. Return on equity (ROE) and return on assets (ROA) are also negative, indicating that the company generates losses from its operations. The balance sheet shows a debt-to-equity ratio of 5.84, with $20.68 million in debt and $78.95 million in cash. The valuation context for BioLife Solutions is marked by a high forward price-to-earnings (P/E) ratio of 158.19, indicating that investors are willing to pay significantly more than the company's earnings suggest it is worth. Revenue growth has been steady, with a year-over-year increase of 31.2%. However, earnings growth data for the same period is unavailable.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About BioLife Solutions, Inc.
BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction tools, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; and the ThawSTAR line include automated thawing devices for frozen cell and gene therapies packaged in cryovials and cryobags. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals. It markets and sells its products directly, as well as through third party distributors. The company was incorporated in 1987 and is headquartered in Bothell, Washington.
Visit website →Key Statistics
- Market Cap
- $1.22B
- P/E Ratio
- N/A
- 52-Week High
- $29.62
- 52-Week Low
- $19.10
- Avg Volume
- 359.26K
- Beta
- 1.93
Company Info
- Industry
- Medical Instruments & Supplies
- Exchange
- NCM
- Country
- United States
- Employees
- 159